Enhanced SOX2 expression in retinoblastoma tissues and peripheral blood is associated with the clinicopathological characteristics of the disease

Tong,Boding; Zeng,Jiexi; Wu,Yujie; Xiong,Wei

doi:10.3892/ol.2015.2857

Enhanced SOX2 expression in retinoblastoma tissues and peripheral blood is associated with the clinicopathological characteristics of the disease

Authors:
- Boding Tong
- Jiexi Zeng
- Yujie Wu
- Wei Xiong
View Affiliations

Affiliations: Department of Ophthalmology and Eye Research Center, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: January 7, 2015 https://doi.org/10.3892/ol.2015.2857
Pages: 1244-1248

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the association between the expression of sex‑determining region Y box 2 (SOX2) in retinoblastoma (Rb) tissues and peripheral blood, and the clinicopathological characteristics of Rb. The expression of SOX2 in Rb tissues was detected by immunohistochemical staining and western blot analysis. SOX2 expression in the peripheral blood of children with Rb was determined using quantitative real‑time polymerase chain reaction. The correlation between SOX2 expression and the clinicopathological characteristics of Rb was analyzed using χ2 tests. The positive rate of SOX2 in Rb tissues was 82.2%, while the expression of SOX2 in the control group tissues was negative. Western blot analysis detected a higher expression of SOX2 in the Rb tissues than in the control group tissues. Poorly differentiated Rb tissues exhibited significantly higher levels of SOX2 expression compared with the well‑differentiated Rb tissues. SOX2 expression was higher in the peripheral blood of children with Rb than in individuals from the control group. The level of SOX2 expression in the peripheral blood of the poorly differentiated group was higher than that of the well‑differentiated group. Enhanced SOX2 expression in Rb tissues and peripheral blood was closely associated with the clinicopathological characteristics of Rb. Therefore, SOX2 may be a novel target biomarker for the clinical diagnosis and treatment of Rb.

View Figures

View References

1	Villegas VM, Hess DJ, Wildner A, et al: Retinoblastoma. Curr Opin Ophthalmol. 24:581–588. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jehanne M, Brisse H, Gauthier-Villars M, et al: Retinoblastoma: recent advances. Bull Cancer. 101:380–387. 2014.(In French). PubMed/NCBI
3	Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, et al: Retinoblastoma. Orphanet J Rare Dis. 1:31–41. 2006. View Article : Google Scholar : PubMed/NCBI
4	Temming P, Eggert A, Bornfeld N, et al: Diagnosis and treatment of retinoblastoma: current strategies for effective tumour control and preservation of vision. Klin Monbl Augenheilkd. 230:232–242. 2013.(In German). PubMed/NCBI
5	Hilgendorf KI, Leshchiner ES, Nedelcu S, et al: The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev. 27:1003–1015. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lai D, Visser-Grieve S and Yang X: Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep. 32:361–374. 2012. View Article : Google Scholar : PubMed/NCBI
7	Sarkar A and Hochedlinger K: The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 12:15–30. 2013. View Article : Google Scholar : PubMed/NCBI
8	Liu K, Lin B, Zhao M, et al: The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 25:1264–1271. 2013. View Article : Google Scholar : PubMed/NCBI
9	Teicher BA: Targets in small cell lung cancer. Biochem Pharmacol. 87:211–219. 2014. View Article : Google Scholar
10	Lipka AF, Verschuuren JJ and Titulaer MJ: SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. Ann N Y Acad Sci. 1275:70–77. 2012. View Article : Google Scholar
11	Linn Murphree A: Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 18:41–53. 2005. View Article : Google Scholar : PubMed/NCBI
12	Cecchini MJ, Thwaites M, Talluri S, et al: A retinoblastoma allele that is mutated at its common E2F interaction site inhibits cell proliferation in gene targeted mice. Mol Cell Biol. 34:2029–2045. 2014. View Article : Google Scholar : PubMed/NCBI
13	Liu R, Zhang XH, Zhang K, et al: 5-Aza-2′-deoxycytidine inhibits retinoblastoma cell by reactivating epigenetically silenced RASSF1A gene. Int J Ophthalmol. 7:51–56. 2014.
14	Thériault BL, Dimaras H, Gallie BL and Corson TW: The genomic landscape of retinoblastoma: a review. Clin Experiment Ophthalmol. 42:33–52. 2014. View Article : Google Scholar : PubMed/NCBI
15	Madhavan J, Ganesh A and Kumaramanickavel G: Retinoblastoma: from disease to discovery. Ophthalmic Res. 40:221–226. 2008. View Article : Google Scholar : PubMed/NCBI
16	Xin GH, Zhao XH, Liu D, et al: Effect of VEGF-targeted antisense gene therapy on retinoblastoma cell line SO-RB50 in vitro and in vivo. Int J Ophthalmol. 5:440–447. 2012.PubMed/NCBI
17	Mhashilkar AM, Schrock RD, Hindi M, et al: Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med. 7:271–282. 2001.PubMed/NCBI
18	Popovic J, Stanisavljevic D, Schwirtlich M, et al: Expression Analysis of SOX14 during retinoic acid induced neural differentiation of embryonal carcinoma cells and assessment of the effect of its ectopic expression on SOXB members in HeLa Cells. PLoS One. 9:e918522014. View Article : Google Scholar : PubMed/NCBI
19	Lin IY, Chiu FL, Yeang CH, et al: Suppression of the SOX2 neural effector gene by PRDM1 promotes human germ cell fate in embryonic stem cells. Stem Cell Reports. 2:189–204. 2014. View Article : Google Scholar : PubMed/NCBI
20	Weina K and Utikal J: SOX2 and cancer: current research and its implications in the clinic. Clin Transl Med. 3:192014. View Article : Google Scholar : PubMed/NCBI
21	Jia X, Li X, Xu Y, et al: SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol. 3:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
22	Fujii T, Shimada K, Tatsumi Y, et al: Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun. Nov 22–2014.(Epub ahead of print).
23	Chou MY, Hu FW, Yu CH and Yu CC: Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells. Oral Oncol. 51:31–39. 2015. View Article : Google Scholar
24	Wadhwa L, Bond WS, Perlaky L, et al: Embryonic retinal tumors in SV40 T-Ag transgenic mice contain CD133+ tumor-initiating cells. Invest Ophthalmol Vis Sci. 53:3454–3462. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhang J, Benavente CA, McEvoy J, et al: A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 481:329–334. 2012.PubMed/NCBI
26	Seigel GM, Campbell LM, Narayan M and Gonzalez-Fernandez F: Cancer stem cell characteristics in retinoblastoma. Mol Vis. 11:729–737. 2005.PubMed/NCBI
27	Seigel GM, Hackam AS, Ganguly A, et al: Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 13:823–832. 2007.PubMed/NCBI